Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial.
J Glob Antimicrob Resist
; 32: 44-47, 2023 03.
Article
de En
| MEDLINE
| ID: mdl-36572146
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
COVID-19
Type d'étude:
Clinical_trials
Limites:
Humans
Langue:
En
Journal:
J Glob Antimicrob Resist
Année:
2023
Type de document:
Article
Pays de publication:
Pays-Bas